Dr. Rubino is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3521 Haworth Dr
Raleigh, NC 27609Phone+1 919-782-1806Fax+1 919-782-4756
Education & Training
University of North Carolina HospitalsResidency, Internal Medicine, 1983 - 1986
Uconn School Of MedicineClass of 1983
Certifications & Licensure
NC State Medical License 1984 - 2025- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Professional EHR, Allscripts, 2011-2012
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2013
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2011-2013
- Join now to see all
Clinical Trials
- 12-Week Study of Plecanatide for CIC (The National CIC3 Study) Start of enrollment: 2014 Apr 01
- Safety and Effectiveness Study of a Non-Crosslinked HA Alkylamide HYADD(TM) 4 Hydrogel for Osteoarthritis of the Knee Start of enrollment: 2014 Jun 01
- A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. Start of enrollment: 2020 Apr 30
Publications & Presentations
PubMed
- 22 citationsImmunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and olderRobert W. Frenck, Anne Fiquet, Alejandra Gurtman, Martin van Cleeff, Matthew Davis
Vaccine. 2016-06-24 - 32 citationsLipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.John Rubino, Diane E. MacDougall, Lulu Ren Sterling, Stephanie E. Kelly, James M. McKenney
Journal of Clinical Lipidology. 2019-05-01 - 24 citationsImmunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.Kristina A. Bryant, Robert W. Frenck, Alejandra Gurtman, John Rubino, John J. Treanor
Vaccine. 2015-10-26
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
